<DOC>
	<DOCNO>NCT01476813</DOCNO>
	<brief_summary>dose-finding study ass optimal dose glycopyrrolate daily dose top BDP/FF COPD patient .</brief_summary>
	<brief_title>Randomized Cross Over Study Assess Efficacy Safety BDP/FF Glycopyrrolate</brief_title>
	<detailed_description>A MULTICENTRE , RANDOMISED , DOUBLE-BLIND , ACTIVE-CONTROLLED , 4-WAY CROSS-OVER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF A FREE COMBINATION OF 3 DOSES OF GLYCOPYRROLATE WITH FIXED COMBINATION BECLOMETHASONE DIPROPIONATE PLUS FORMOTEROL ( FOSTERÂ® ) IN A METERED DOSE INHALER FOR THE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE ( COPD )</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>COPD 40 year age ( 30 60 % postbronchodilator FEV1 predictive value ) Patients Double Patients triple therapy ( 1 Mo prior Screening ) Pregnant lactate woman Patients experience COPD exacerbation require use systemic steroid and/or antibiotic , hospitalization concommitant diseases impact feasibility safety</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>